clinical development
[용어속성] Term
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
단일 용량 mRNA 백신은 SARS-CoV-2로부터 hACE2 형질전환 마우스를 장기간 보호합니다
Article
[키워드] Antibody Response
BALB/c mice
candidate
Cellular responses
clinical development
clinical trial
clinical trials
convalescent patient
Convalescent patients
COVID-19 pandemic
demonstrated
elicited
expressing
global health
hACE2
Health
immunization
induce
late phase
lung
Lungs
mice
mRNA
mRNA vaccine
mRNA-based vaccine
Neutralizing antibodies
neutralizing antibody
notable
nucleoside
nucleoside-modified mRNA
provide
provided
raised
rapid expansion
RBD
Re-infection
regimen
RNA vaccines
robust
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 RBD
SARS-CoV-2 Spike RBD
SARS-CoV-2 vaccine
sera
short duration
single dose
Taking
the SARS-CoV-2
These data
transfer
transgenic mice
vaccination
Vaccine
widespread
[DOI] 10.1038/s41467-021-21037-2 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41467-021-21037-2 PMC 바로가기 [Article Type] Article
Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm
Review
[키워드] acute respiratory syndrome
chemokine
chemokines
clinical development
consequence
Consequences
coronavirus
coronavirus disease
COVID-19
COVID-19 infection
COVID-19 infections
CRS
cytokine
Cytokine release syndrome
Cytokine storm
Effects
Factor
hallmark
host response
Hyperinflammatory
Infection
pandemic
pathophysiological
Pneumonia
progression
SARS-CoV-2
selected
Severe respiratory distress
storm
Strategy
syndrome
targeting
Treatment
upregulated
virus
[DOI] 10.3390/biom11010091 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/biom11010091 PMC 바로가기 [Article Type] Review
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial
COVID-19 폐렴 환자에서 호흡 악화 예방을 위한 BIO101의 효능 및 안전성 테스트(COVA 연구): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
20-hydroxyecdysone
absence
accumulation
ACE2
Activation
acute respiratory distress
acute respiratory distress syndrome
adaptive
addition
administration
Airway Pressure
all-cause mortality
ALT
Alter
amenorrhea
Analysis
angiotensin
angiotensin converting enzyme
angiotensin converting enzyme 2
Angiotensin converting enzyme-2
Anti-inflammatory
anticipated
approved
ARDS
arterial oxygen saturation
AST
Asymptomatic
balance
baseline
being
Belgium
beneficiary
Bilirubin
BIO101
Biomarker
Biomarkers
birth control
blinded
Brazil
breath
Cardiomyopathy
Care
Caregivers
caused
clinical development
Clinical finding
Clinical findings
clinical picture
co-morbidities
co-morbidity
collected
Compliance
condition
condom
conducted
confirmation
Consumption
Continuous
Continuous Positive Airway Pressure
Contraception
contraceptive method
coronavirus disease
COVID-19
COVID-19 infection
COVID-19 infection symptom
COVID-19 infection symptoms
COVID-19 patient
COVID-19 patients
criteria
criterion
daily dose
Day
death
defined
Department
Deterioration
develop
diabetes
diagnosis of COVID-19
dialysis
discharge
discharged
disease
dissemination
DMC
dose
double-blind
downstream
ECMO
Effect
effective
Efficacy
Efficacy and safety
EGFR
element
eligible participant
Eligible participants
endotracheal tube
Endpoint
enzyme
etonogestrel
EudraCT
European
evaluate
event
Evidence
evidence of
exclusion criteria
expected
exploratory
extracorporeal membrane oxygenation
female
female participants
Final
FiO2
Flow
following
form
France
French
functional
Gault
Gender
healthcare
healthcare facility
heart disease
High-flow oxygen
higher risk
hospital
hospital care
Hospitalization
Hospitalized
hypersensitivity
hypertension
IBM
ICF
Imbalance
include
Inclusion
independent
indication
Infection
Inflammation
informed consent form
injection
Interim analyses
interim analysis
Intervention
intrauterine device
Intubated
Invasive mechanical ventilation
IWRS system
lactating
limit
Liver function
liver function tests
male participants
marker
Mas receptor
maximum
measure
mechanical ventilation
medical intervention
medication
medications
minute
moderate
morbidities
Moribund
Mortality
mouth
Multiorgan dysfunction
muscles
myocarditis
negative urine pregnancy test
Non-COVID-19
number
obesity
objective
observation
offer
Older
oral contraceptive
outcome
outlined
oxygen
Part
participant
partner
pathway
Pathways
patients with COVID-19
patients with SARS-CoV-2
PCR
performed
Pericarditis
Physical examination
Placebo
placebo-controlled
Pneumonia
positive airway pressure
post-intervention
post-menopausal
powder
pregnancy test
pressure
primary endpoint
proof
proportion
Proportion of participant
protocol
public health
randomised
randomised controlled trial
randomization
RAS
reached
receive
receiving
receptor
recruited
recruitment
Registered
renal
renal disease
renal insufficiency
Renin
renin angiotensin system
renin-angiotensin system
reproduction
required
resource
respiratory
Respiratory distress syndrome
Respiratory failure
Respiratory function
respiratory symptoms
restored
risk
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV2
SARS-CoV2 spike protein
second
secondary
secondary endpoint
security
severe pneumonia
Shock
Social Security
specimen
Sperm
Spike protein
SpO2
Statistical power
status
Sterilization
Stratification
stratified
study medication
Study protocol
supplementary material
survival
suspicion
Symptom
syndrome
tachypnea
target population
tested
Testing
the primary endpoint
therapeutic
therapeutic option
tissue
Tolerability
Total
total bilirubin
Treatment
treatment arm
treatment period
Triage
Trial
Trial registration
ULN
Urine
USA
variety
vasectomy
Version
Viral load
water
website
[DOI] 10.1186/s13063-020-04998-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04998-5 PMC 바로가기 [Article Type] Letter
Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
530
[키워드] ACE2
acute respiratory syndrome
affected
age
androgen
Androgen receptor
androgen signaling
angiotensin-converting enzyme 2
antagonist
approved
BET
BET inhibitors
Cell
cells
characterized
clinical development
Cohort
coronavirus
COVID-19
COVID-19 pandemic
Critical
domain
effective
elevated
epidemiological
expression
Factor
female
greater
Host
host protein
in vitro
indication
inhibited
inhibitor
Lung epithelial cells
male
morbidity
Mortality
New
Prevent
prevention of COVID-19
Prostate
Prostate cancer
protease
Protective
Protein
receptor
regulate
replicate
responsible
Result
SARS-CoV-2
SARS-CoV-2 entry factor
SARS-COV-2 infection
serine 2
Sex hormones
Significance
smoking
subset
suggested
Support
Supporting
targeting
therapeutic target
TMPRSS2
transcriptional
transcriptional regulation
transmembrane
Treatment
viable treatment
virus
[DOI] 10.1073/pnas.2021450118 PMC 바로가기 [Article Type] 530
[DOI] 10.1073/pnas.2021450118 PMC 바로가기 [Article Type] 530
Biomarkers for the clinical development of antiviral therapies
Review
[키워드] Antiviral
Biomarker
clinical development
Drug discovery
virus
[DOI] 10.1002/cyto.b.21974 [Article Type] Review
[DOI] 10.1002/cyto.b.21974 [Article Type] Review
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19
SARS-CoV-2에 의한 내피 감염 및 조절 장애: COVID-19의 증거 및 주의 사항
Review
[키워드] ACE2
acute respiratory syndrome
ADAM17
angiotensin
Angiotensin-converting enzyme
angiotensin-converting enzyme 2
binding
bradykinin–kallikrein pathway
caused
cellular receptor
clinical development
Complication
contribute
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patients
Deleterious
direct infection
downregulation
dysfunction
Endothelial cell
endothelial cells
Endothelial dysfunction
Endothelium
event
Evidence
evidence of
exacerbate
global public health
human lung
immunothrombosis
include
infect
Inflammatory
lead
manifestation
Neurological diseases
pandemic
parameter
pericyte
Protein
RAAS
recent
renal
respiratory
Respiratory illness
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 replication
severe COVID-19
severe disease
spike
Spike protein
therapeutic agent
therapeutic agents
Therapeutics
thrombotic
Viral
viral spike protein
[DOI] 10.3390/v13010029 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/v13010029 PMC 바로가기 [Article Type] Review
Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand
Article
[키워드] clinical development
COVID-19
Demand
dose
faster
feasibility
hypothetical
impacted
lower dose
Messenger RNA
mRNA
mRNA vaccines
overcome
pandemic-response vaccine production
Pandemics
producing
Production
production process modelling
required
resource
resources
RNA
RNA vaccine
RNA vaccines
saRNA vaccines
scale
techno-economic analysis
time
titre
vaccination
Vaccine
vaccine dose
Vaccines
Volume
[DOI] 10.3390/vaccines9010003 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/vaccines9010003 PMC 바로가기 [Article Type] Article
Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19
Article
[키워드] activity
acute respiratory distress
acute respiratory syndrome
Adverse drug reaction
Antiviral effect
Bioavailability
Cell
characterized
clinical development
co-morbidity
coronavirus
coronavirus disease
COVID-19
COVID-19 drugs
Cytokine storm
demonstrated
drug
Drug development
Efficacy
exhibit
highlighting
increased risk
Inflammation
innate immune response
joint inflammation
mechanism
Mild
occurred
older patient
Organ failure
oxidative stress
pandemic
physiological action
polymorph
Preclinical
prevention
reactive oxygen specy
ROS
safety profile
SARS-CoV-2
scavenging
similarity
sodium
stability
syndrome
systemic inflammatory response
[DOI] 10.3390/ijms21228803 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/ijms21228803 PMC 바로가기 [Article Type] Article
COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir
COVID-19 팬데믹: Cyclophilin 억제제 Alisporivir를 되살릴 시간
Article
Published on
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 비임상, 임상, 치료제,
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 비임상, 임상, 치료제,
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
alisporivir
Antiviral
breath
caused
clinical development
clinical endpoint
coronavirus
coronavirus disease
Coronavirus disease 2019
Coronavirus infection
Coronaviruses
COVID-19
cyclophilin
cyclophilin.
cyclosporine
cyclosporine A
Epidemic
form
include
Infection
life cycle
Middle East
Middle East respiratory syndrome Coronavirus
Patient
Phase 3
Pneumonia
preclinical data
reached
respiratory
respiratory syndrome coronavirus
risk
SARS-CoV-2
SARS-COV-2 infection
severe acute respiratory syndrome Coronavirus
severity
tested
therapeutic option
time
treat
Treatment
treatment of COVID-19
Virological
[DOI] 10.1093/cid/ciaa587 PMC 바로가기 [Article Type] Article
[DOI] 10.1093/cid/ciaa587 PMC 바로가기 [Article Type] Article